- Home
- XPER vs ALLO Comparison
XPER vs ALLO Comparison
Compare XPER & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPER
- ALLO
- Stock Information
- Founded
- XPER 1990
- ALLO 2017
- Country
- XPER United States
- ALLO United States
- Employees
- XPER N/A
- ALLO N/A
- Industry
- XPER Semiconductors
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XPER Technology
- ALLO Health Care
- Exchange
- XPER Nasdaq
- ALLO Nasdaq
- Market Cap
- XPER 463.5M
- ALLO 427.7M
- IPO Year
- XPER 2003
- ALLO 2018
- Fundamental
- Price
- XPER $8.87
- ALLO $2.17
- Analyst Decision
- XPER Strong Buy
- ALLO Strong Buy
- Analyst Count
- XPER 3
- ALLO 10
- Target Price
- XPER $19.00
- ALLO $10.06
- AVG Volume (30 Days)
- XPER 282.4K
- ALLO 9.8M
- Earning Date
- XPER 02-26-2025
- ALLO 03-13-2025
- Dividend Yield
- XPER N/A
- ALLO N/A
- EPS Growth
- XPER N/A
- ALLO N/A
- EPS
- XPER N/A
- ALLO N/A
- Revenue
- XPER $508,559,000.00
- ALLO $43,000.00
- Revenue This Year
- XPER N/A
- ALLO N/A
- Revenue Next Year
- XPER $2.28
- ALLO N/A
- P/E Ratio
- XPER N/A
- ALLO N/A
- Revenue Growth
- XPER N/A
- ALLO 26.47
- 52 Week Low
- XPER $6.89
- ALLO $1.32
- 52 Week High
- XPER $12.29
- ALLO $5.78
- Technical
- Relative Strength Index (RSI)
- XPER 39.39
- ALLO 55.14
- Support Level
- XPER $8.83
- ALLO $1.32
- Resistance Level
- XPER $9.34
- ALLO $3.78
- Average True Range (ATR)
- XPER 0.27
- ALLO 0.36
- MACD
- XPER -0.01
- ALLO 0.10
- Stochastic Oscillator
- XPER 16.28
- ALLO 34.55
About XPER Xperi Inc.
Xperi Inc consumer and entertainment technology company. Its offering comprises a portfolio of software and services. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.